Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 studyMarina Chiara Garassino, Inmaculada Ramos García, Byoung Chul Cho et al.|The Lancet Oncology|2018Cited by 579
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast CancerXavier Pivot, Semiglazov Vf, Alexey Manikhas et al.|Journal of Clinical Oncology|2015Cited by 253
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with NivolumabUgo De Giorgi, Cora N. Sternberg, Giuseppe Procopio et al.|Clinical Cancer Research|2019Cited by 240
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trialRafael Rosell, Rolf A. Stahel, Urania Dafni et al.|The Lancet Respiratory Medicine|2017Cited by 184
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancerLucio Crinò, Angelo Delmonte, Giuseppe Bronte et al.|Lung Cancer|2019Cited by 158